The story of the erectile dysfunction drug presents a complex picture for investors. While the initial release generated substantial returns, the lapse of its patent opened the door to generic alternatives, https://liviadfew175085.jts-blog.com/40387985/sildenafil-and-big-pharma-a-volatile-opportunity